Fluoropyrimidine Treatment in Patients with Dihydropyrimidine Dehydrogenase (DPD) Deficiency: Guidance for Clinicians
To provide clinicians with guidance on implementation of routine, pre-treatment DPYD testing and genotype-guided dosing for cancer patients with planned fluoropyrimidine treatment in Ontario.
Cancer patients who are candidates for systemic treatment with fluoropyrimidines (5-fluorouracil or capecitabine)
Intended Guideline Users
Health care providers involved in the care of cancer patients who have planned systemic treatment with fluoropyrimidines (medical oncologists, nurses, pharmacists)